Library
ADB-PINACA izomer 2
ADB-PINACA isomer 2 is a positional isomer of Schedule I ADB-PINACA with an isoleucine-derived side chain rather than tert-leucine. Expected to have sub-nanomolar CB1 affinity similar to related compounds (likely Ki < 1 nM), meaning single-milligram doses can cause severe intoxication, catatonia, or seizures. Fatalities and acute kidney injury have been documented with the parent compound and closely related isomers. Laboratory detection standards are limited; routine drug screens rarely detect this isomer, so users may test negative while impaired. Using a milligram scale (0.001 g readability) and thoroughly dissolving powder into carrier (PG/VG e-liquid or acetone for herb spraying) is essential for harm reduction.
Also known as: ADB-PINACA iso-2
Classification
- Chemical: Cannabinoid
- Tag: Habit-Forming
- Tag: Hallucinogen
- Tag: Indazolecarboxamide
- Tag: Research-Chemical
Effects
- Body Heaviness
- Tachycardia And Palpitations
- Dry Mouth And Eyes
- Nausea
- Motor Incoordination
- Seizure
- Euphoria
- Time Distortion
- Enhanced Music Appreciation
- Shortterm Memory Suppression
- Anxiety Or Paranoia
- Compulsive Redosing
- Closedeye Visuals
- Visual Hallucinations
- Increased Music Appreciation
- Open Eye Visuals
- Closed Eye Visuals
- Closedeye Imagery
Routes of Administration
Smoked
Dosage
- Threshold: ≤0.5 mg
- Light: 0.5 – 1 mg
- Common: 1 – 2 mg
- Strong: 2 – 3 mg
- Heavy: ≥3 mg (dangerous)
Duration
- Onset: 0.01-0.03 h
- Peak: 0.08-0.42 h
- Offset: 0.75-1.5 h
- After Effects: 1.5-5 h
- Total Duration: 1-2 h
Vaporized
Dosage
- Threshold: ≤0.4 mg
- Light: 0.4 – 0.8 mg
- Common: 0.8 – 1.6 mg
- Strong: 1.6 – 2.5 mg
- Heavy: ≥2.5 mg
Duration
- Onset: 0.01-0.03 h
- Peak: 0.08-0.42 h
- Offset: 0.75-1.5 h
- After Effects: 4 h
Oral
Dosage
- Threshold: 0.5 mg
- Light: 0.5 – 1 mg
- Common: 1 – 1.5 mg
- Strong: 1.5 – 2 mg
- Heavy: >2 mg
Duration
- Onset: 0.17-0.5 h
- Peak: 0.5-1.5 h
- Offset: 1-2 h
- After Effects: 2-6 h
- Total Duration: 2-4 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.
